Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia
Status:
Completed
Trial end date:
2019-01-17
Target enrollment:
Participant gender:
Summary
Assessed the efficacy of deferasirox in patients with non-transfusion dependent thalassemia
based on change in liver iron concentration from baseline after 52 weeks of treatment.
Provided further assessment of the long-term efficacy and safety of deferasirox in NTDT
patients with iron overload (LIC ≥ 5 mg Fe/g liver dw and SF ≥ 300 ng/mL) for up to 260
weeks.